Oseltamivir Market Size is Expected to Reach $744.3 Billion by 2027


« The oseltamivir market | IndustryARC »

Elevated Spread of Contagions Post COVID-19 Expected to Drive Oseltamivir Market

Oseltamivir Market The size is expected to reach $744.3 billion by 2027 growing at a CAGR of 3.1% during the forecast period 2022-2027. Oseltamivir belongs to the category of sialic acid analog antiviral medications which are widely used to treat cases of influenza A and influenza B. They are transmissible viral contagions that lead to respiratory complications such as fever, nausea, gastro -enteritis, cough, pain. in the throat, fatigue. In maximum cases, the symptoms can be resolved by antiviral drugs, but the persistence of the flu can lead to serious health problems that can be life-threatening. Neuraminidase inhibitors such as Tamiflu and Relenza prevent the spread of infections such as influenza A and B by simply blocking the replication process. Increase in respiratory complications along with geriatric faction of the population has increased the flow of hard cash in the research and development of new drugs, and increasing knowledge among the people are factors that will boost the growth of the industry of oseltamivir for the period 2022-2027.

Oseltamivir Market Segment Analysis – By Treatment

The oseltamivir market based on treatment type can be further segmented into influenza A and influenza B. The influenza A segment held the largest share of the overall market in 2021. The growth is driven by the increase in prevalence of cases inflicted by influenza A. Its spread is not only limited to human beings like influenza B. Its prevalence is quite common in animals and birds like pigs, horses, ducks, chickens and many others. On the other hand, it is a more serious form because it causes more severe symptoms than influenza B.

Moreover, the influenza A segment is estimated to be the fastest growing with a CAGR of 3.7% over the forecast period 2022-2027. This growth is due to the proliferation of health consciousness among people, greater focus on research and development of curative drugs by pharmaceutical companies and research institutes. Additionally, according to the US CDC, the flu that has been attributed to viruses had a prevalence of 1% during the week ending November 20, 2021.

For more information on the oseltamivir market @


Report price: $4500 (single-user license)

Oseltamivir Market Segment Analysis – By Distribution Channel

The oseltamivir market based on distribution channel can be further segmented into hospitals, retail pharmacies, pharmacies, local medical stores, online platforms. The retail pharmacy segment held the largest share in 2021. The growth is due to factors such as the presence on the board of retail pharmacies even in pastoral areas. On the other hand, a maximum of drugs in these stores are available without a prior prescription from a doctor.

Moreover, the online segment is estimated to be the fastest growing segment with a CAGR of 4.1% over the forecast period 2022-2027. This growth is due to rapid digitization resulting from improved online configuration. Shopping online instead of visiting pharmacies in person encompasses an overabundance of benefits such as convenient shopping, time saving, general presence of digital platforms as their delivery services are ubiquitous. Additionally, Fluvir, a 75MG capsule of Oseltamivir is available on a named digital platform – Tata 1Mg is available for INR 394, against the MRP of INR 539. Strategies such as cashback, discount coupons, and subscriptions are the plausible factors that can fuel the growth of the segment.

Oseltamivir Market Segment Analysis by Geography

Geography-based oseltamivir market can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America held the largest share with 35% of the overall market in 2021. The growth of this segment is due to factors such as health conscious population, advanced healthcare infrastructure such as hospitals and with world-class research laboratories in the United States and Canada, an extensive network of retail pharmacies and pharmacies. In addition, the fiscal year 2022 budget proposes $131.8 billion in discretionary budget authority and $1.5 trillion in mandatory funding in the United States.

However, Asia-Pacific is expected to be the fastest growing segment during the forecast period 2022-2027. This growth is due to the colossal population of Asian countries like India and China, resulting in an immersive spread of contagion, thriving economies allowing governments to invest countless amounts of wealth in research and development of new drugs and refine the already existing network of hospitals and clinics. .

Oseltamivir Market Drivers

Elevated Spread of Post-COVID-19 Contagions Expected to Boost Product Demand

There has been an upsurge in several communicable infectious diseases around the world following COVID-19. According to the report, as shutdowns come to an end and people return to normal lives, flu cases could rise precipitously as human-to-human interactions recur. In addition, the elderly population is increasing and the declining immunities of the elderly are more prone to respiratory diseases, which may increase the overall demand for antiviral drugs. According to a US clinical report of 265,492 samples tested of the total positive cases, 74.4% were found positive with influenza A, while 25.6% with influenza B. This shows us how many cases of influenza A dominate in terms of total infections.

Growing flows of research wealth should drive demand for products

After COVID-19, there has been a massive shift in people’s general thinking about health. People’s attitudes are changing from treatment to disease prevention, and their overall awareness of these drugs is increasing day by day. On the other hand, governments around the world are allocating more funds to refine the existing health infrastructure and building new infrastructure. By the end of 2028, US healthcare spending is expected to reach 20% of its GDP (about $6.2 trillion). All these aforementioned factors are expected to fuel the growth of the oseltamivir market.

Direct purchase @ https://www.industryarc.com/purchasereport.php?id=501917

Oseltamivir Market Challenges

Side effect associated with oseltamivir is expected to hamper market growth

One factor that is expected to reduce the growth of the aforementioned market is the side effects associated with the use of such antiviral drugs. Consuming oseltamivir can lead to several health complications such as nausea, gastroenteritis, stomach pain. In a few cases, it can lead to serious health complications such as heart attack, severe liver disease, kidney problems which can be life threatening. These disadvantages can strangle the growth of the overall market.

Oseltamivir Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographic expansions are key strategies adopted by Oseltamivir market players. Key Companies in this market are-


Nagar Medico

NATCO Pharma Limited


Triveni Chemicals

Lotus International

straight health care

F. Hoffmann-La Roche Ltd.

still pharmaceuticals

Zydus Cadila


On November 12, 2021, an antiviral drug “Oselavir” was launched in the Chinese market by Indian pharmaceutical company Hetero Healthcare and Shenzhen Beimei, a Chinese player. These two companies have been in partnership for a long time. It will be available in China in the galenic form of 12.5 ml: 75 mg for oral suspension. In addition, the dosage can be given to children over 2 weeks old, except for adults and adolescents.

On June 19, 2021, a few cases of influenza A (H1N1) were discovered in a detention center located on the Texas border. The researcher claimed that the aforementioned flu exhibits properties that are resistant to the effects of the antiviral drug “Oseltamivir”. A total of four cases have been reported, including hemagglutinin belonging to a subclade that can allow the virus to escape from pre-existing immunity. Additionally, virologists have reported concerns about this.

On February 15, 2021, “Lupin Pharmaceuticals and AuroMedics Pharma” Baltimore and branches of two Indian pharmaceutical companies based east of Windsor recalled several antiviral drugs from the US market due to impurities. The drugmaker has recalled around 46,749 vials of the antiviral drug Oseltamivir for oral suspension. The product was manufactured in the Aurangabad-Maharashtra plant in India.

Key points to remember:

Geographically, North America oseltamivir market accounted for the highest revenue share in 2021. However, Asia-Pacific is poised to dominate the market during 2022-2027.

The increasing prevalence of transmissible contagions is said to be the major driver for the growth of the oseltamivir market. However, many health-related side effects such as insomnia would reduce the market growth.

A detailed analysis of the strengths, weaknesses and opportunities of key players operating in the market will be provided in the Oseltamivir market report.

Relevant links:

Generic drugs market


For more Life Sciences and Healthcare Market Reports, please Click here

About IndustryARC: IndustryARC mainly focuses on market research on advanced technologies and new applications. Our custom research services are designed to provide insights into the constant flow of the global supply and demand gap in markets. Our strong team of analysts allows us to respond quickly to client research needs, with a variety of options for your business. Any other custom requirements can be discussed with our team, email [email protected] to learn more about our consulting services.

Media Contact
Company Name: IndustryCRA
Contact: Mr Venkat Reddy
E-mail: Send an email
Call: (+1) 970-236-3677
Town: Hyderabad
The country: India
Website: https://www.industryarc.com/

Press release issued by ABNewswire.com

To view the original version on ABNewswire, visit: Oseltamivir Market Size is Expected to Reach $744.3 Billion by 2027


Comments are closed.